Bispecifics for I&I: Bypassing combination complexity

While precision medicine strategies that sacrifice market size for better responder rates have been a tough sell in the inflammation and immunology field, companies are finding other ways to boost responses. One emerging approach: bispecific antibodies that block two inflammatory pathways instead of one.

In cancer, bispecifics got their start as T cell engagers and have since diversified into a wider array of antitumor mechanisms. A major theme is the ability to deliver added functionality over combinations of mAbs against the same targets. They can, for example, localize therapies to the tumor microenvironment, avoiding tox, and ward off resistance by blocking both a cancer target and its key resistance mechanism...